A new generation of HSP90 inhibitors with improved toxicities are under active clinical investigation as single drugs or in combination with other therapeutics in patients with various cancers, including lung [27,28], brain [29], and breast [30,31] cancers as well as sarcomas [32,33]. Here, HSP90AA1 is linked to cancer.